- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Spectral AI submitted its DeepView diagnostic to the FDA and filed Form 10-Q with the Securities and Exchange Commission (Bangladesh).
Spectral AI submitted a De Novo application to the FDA and announced financial results from Dallas.
6 reports, 2 independent
Updated Aug 1
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Spectral AI submitted a De Novo application to the FDA and announced financial results from Dallas.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Spectral AI filed a De Novo application with the FDA.1 source
Spectral AI's FDA submission is supported by federal funding from BARDA and HHS.1 source
Keep exploring
The entities involved
Related events
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- GSK is submitting data to the FDA regarding potential expansion of its drug indications.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
Coverage
Newest first; wire copies grouped- GlobeNewswireSpectral AI Announces 2025 Second Quarter Financial Results Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 Million Strong Cash position
- GlobeNewswireSpectral AI Schedules 2025 Second Quarter Financial Results and Conference Call DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the
- Insider MonkeySpectral AI (MDAI) Submits FDA Application for DeepView Burn Assessment System Spectral AI, Inc. (NASDAQ:MDAI) is one of the most popular AI penny stocks to buy according to billionaires. On June 30,
- Unknown outlet
- Unknown outlet